260 related articles for article (PubMed ID: 17387268)
21. The Fanconi anemia ID2 complex: dueling saxes at the crossroads.
Boisvert RA; Howlett NG
Cell Cycle; 2014; 13(19):2999-3015. PubMed ID: 25486561
[TBL] [Abstract][Full Text] [Related]
22. FANCC, FANCE, and FANCD2 form a ternary complex essential to the integrity of the Fanconi anemia DNA damage response pathway.
Gordon SM; Alon N; Buchwald M
J Biol Chem; 2005 Oct; 280(43):36118-25. PubMed ID: 16127171
[TBL] [Abstract][Full Text] [Related]
23. Massively parallel sequencing, aCGH, and RNA-Seq technologies provide a comprehensive molecular diagnosis of Fanconi anemia.
Chandrasekharappa SC; Lach FP; Kimble DC; Kamat A; Teer JK; Donovan FX; Flynn E; Sen SK; Thongthip S; Sanborn E; Smogorzewska A; Auerbach AD; Ostrander EA;
Blood; 2013 May; 121(22):e138-48. PubMed ID: 23613520
[TBL] [Abstract][Full Text] [Related]
24. Functional defects in the fanconi anemia pathway in pancreatic cancer cells.
van der Heijden MS; Brody JR; Gallmeier E; Cunningham SC; Dezentje DA; Shen D; Hruban RH; Kern SE
Am J Pathol; 2004 Aug; 165(2):651-7. PubMed ID: 15277238
[TBL] [Abstract][Full Text] [Related]
25. New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein.
Fei P; Yin J; Wang W
Cell Cycle; 2005 Jan; 4(1):80-6. PubMed ID: 15611632
[TBL] [Abstract][Full Text] [Related]
26. The Chinese hamster FANCG/XRCC9 mutant NM3 fails to express the monoubiquitinated form of the FANCD2 protein, is hypersensitive to a range of DNA damaging agents and exhibits a normal level of spontaneous sister chromatid exchange.
Wilson JB; Johnson MA; Stuckert AP; Trueman KL; May S; Bryant PE; Meyn RE; D'Andrea AD; Jones NJ
Carcinogenesis; 2001 Dec; 22(12):1939-46. PubMed ID: 11751423
[TBL] [Abstract][Full Text] [Related]
27. Heterogeneous activation of the Fanconi anemia pathway by patient-derived FANCA mutants.
Adachi D; Oda T; Yagasaki H; Nakasato K; Taniguchi T; D'Andrea AD; Asano S; Yamashita T
Hum Mol Genet; 2002 Dec; 11(25):3125-34. PubMed ID: 12444097
[TBL] [Abstract][Full Text] [Related]
28. Fanconi anemia pathway heterogeneity revealed by cisplatin and oxaliplatin treatments.
Kachnic LA; Li L; Fournier L; Willers H
Cancer Lett; 2010 Jun; 292(1):73-9. PubMed ID: 20034732
[TBL] [Abstract][Full Text] [Related]
29. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
[TBL] [Abstract][Full Text] [Related]
30. Functional interaction of monoubiquitinated FANCD2 and BRCA2/FANCD1 in chromatin.
Wang X; Andreassen PR; D'Andrea AD
Mol Cell Biol; 2004 Jul; 24(13):5850-62. PubMed ID: 15199141
[TBL] [Abstract][Full Text] [Related]
31. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice.
Houghtaling S; Timmers C; Noll M; Finegold MJ; Jones SN; Meyn MS; Grompe M
Genes Dev; 2003 Aug; 17(16):2021-35. PubMed ID: 12893777
[TBL] [Abstract][Full Text] [Related]
32. Regulation of the activation of the Fanconi anemia pathway by the p21 cyclin-dependent kinase inhibitor.
Rego MA; Harney JA; Mauro M; Shen M; Howlett NG
Oncogene; 2012 Jan; 31(3):366-75. PubMed ID: 21685936
[TBL] [Abstract][Full Text] [Related]
33. The identification of FANCD2 DNA binding domains reveals nuclear localization sequences.
Niraj J; Caron MC; Drapeau K; Bérubé S; Guitton-Sert L; Coulombe Y; Couturier AM; Masson JY
Nucleic Acids Res; 2017 Aug; 45(14):8341-8357. PubMed ID: 28666371
[TBL] [Abstract][Full Text] [Related]
34. Coordination of the recruitment of the FANCD2 and PALB2 Fanconi anemia proteins by an ubiquitin signaling network.
Bick G; Zhang F; Meetei AR; Andreassen PR
Chromosoma; 2017 Jun; 126(3):417-430. PubMed ID: 27277787
[TBL] [Abstract][Full Text] [Related]
35. The ubiquitination machinery of the Fanconi Anemia DNA repair pathway.
Tan W; Deans AJ
Prog Biophys Mol Biol; 2021 Aug; 163():5-13. PubMed ID: 33058944
[TBL] [Abstract][Full Text] [Related]
36. Loss of CHK1 function impedes DNA damage-induced FANCD2 monoubiquitination but normalizes the abnormal G2 arrest in Fanconi anemia.
Guervilly JH; Macé-Aimé G; Rosselli F
Hum Mol Genet; 2008 Mar; 17(5):679-89. PubMed ID: 18029388
[TBL] [Abstract][Full Text] [Related]
37. Bone Marrow Mesenchymal Stem Cells Carrying FANCD2 Mutation Differ from the Other Fanconi Anemia Complementation Groups in Terms of TGF-β1 Production.
Cagnan I; Gunel-Ozcan A; Aerts-Kaya F; Ameziane N; Kuskonmaz B; Dorsman J; Gumruk F; Uckan D
Stem Cell Rev Rep; 2018 Jun; 14(3):425-437. PubMed ID: 29247345
[TBL] [Abstract][Full Text] [Related]
38. Functional interaction between the Fanconi Anemia D2 protein and proliferating cell nuclear antigen (PCNA) via a conserved putative PCNA interaction motif.
Howlett NG; Harney JA; Rego MA; Kolling FW; Glover TW
J Biol Chem; 2009 Oct; 284(42):28935-42. PubMed ID: 19704162
[TBL] [Abstract][Full Text] [Related]
39. High-risk human papillomavirus oncogenes disrupt the Fanconi anemia DNA repair pathway by impairing localization and de-ubiquitination of FancD2.
Khanal S; Galloway DA
PLoS Pathog; 2019 Feb; 15(2):e1007442. PubMed ID: 30818369
[TBL] [Abstract][Full Text] [Related]
40. FANCD2 but not FANCA promotes cellular resistance to type II topoisomerase poisons.
Kachnic LA; Li L; Fournier L; Ferraiolo N; Dahm-Daphi J; Borgmann K; Willers H
Cancer Lett; 2011 Jun; 305(1):86-93. PubMed ID: 21414716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]